BioCentury
ARTICLE | Company News

Tetragenetics, Theranyx deal

June 6, 2016 7:00 AM UTC

The companies partnered to discover and develop therapeutic mAbs against Nav1.6 ( PN4; SCN8A), potassium channel Kv10.1 (KCNH1) and other undisclosed ion channel targets. The partners said they wil...